^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ERY974

i
Other names: ERY974, ERY-974, ERY 974
Associations
Company:
Roche
Drug class:
CD3 agonist, GPC-3 inhibitor
Related drugs:
Associations
2ms
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=179, Active, not recruiting, Chugai Pharmaceutical | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
GPC3 (Glypican 3)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974
9ms
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=179, Recruiting, Chugai Pharmaceutical | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
GPC3 (Glypican 3)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974
3years
Clinical • New P1 trial • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1) • GPC3 (Glypican 3)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974
over3years
[VIRTUAL] ERY974, an Anti-Glypican 3/CD3 Bispecific T Cell-Redirecting Antibody for Treatment of Solid Tumors (PEGS 2021)
ERY974 exerts strong anti-tumor activity against a variety of tumor models including those with a non-inflamed phenotype. In this talk, I will discuss the detailed preclinical characterization of ERY974, including the cytokine release mechanism and potential combination therapies.
IO biomarker
|
GPC3 (Glypican 3)
|
ERY974
over3years
[VIRTUAL] Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors. (AACR 2021)
The observed responses and CRS side effects are markers of ERY974 biologic activity. At doses below 0.81 μg/kg (regimen A), ERY974 was generally well tolerated with a manageable toxicity profile, including ERY-induced CRS which was manageable with steroid administration and anti-IL6R therapy. Further research is required to determine if combined prophylactic anti-IL6R and steroid therapy is a more effective strategy for managing CRS.
Clinical • P1 data
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • GPC3 (Glypican 3) • IL10 (Interleukin 10)
|
CXCL8 elevation
|
ERY974